Physico-Chemical and Biological Properties of Biosimilar and Reference Tissue Plasminogen Activator Products
Recombinant tissue plasminogen activator (international nonproprietary name — alteplase) which was developed by «GENERIUM» (Russia) and received a marketing authorisation in Russia is completely analogous to Actilyse® which is used to treat medical conditions accompanied by thrombosis, such as acute...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Ministry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»
2019-03-01
|
| Series: | Биопрепараты: Профилактика, диагностика, лечение |
| Subjects: | |
| Online Access: | https://www.biopreparations.ru/jour/article/view/207 |
| _version_ | 1826566490293272576 |
|---|---|
| author | V. D. Gusarova M. S. Pantyushenko V. M. Simonov R. R. Shukurov R. A. Khamitov A. Yu. Vishnevskiy |
| author_facet | V. D. Gusarova M. S. Pantyushenko V. M. Simonov R. R. Shukurov R. A. Khamitov A. Yu. Vishnevskiy |
| author_sort | V. D. Gusarova |
| collection | DOAJ |
| description | Recombinant tissue plasminogen activator (international nonproprietary name — alteplase) which was developed by «GENERIUM» (Russia) and received a marketing authorisation in Russia is completely analogous to Actilyse® which is used to treat medical conditions accompanied by thrombosis, such as acute myocardial infarction, pulmonary embolism, and ischemic stroke. The aim of the study was to carry out a comprehensive comparison of physico-chemical and biological properties of Revelyse® and the reference product Actilyse® in order to assess their biosimilarity. Materials and Methods: comparative peptide mapping and determination of comparability of chromatographic profiles of tryptic hydrolysates was performed using RP-HPLC and massspectrometry; the molecular weight distribution was determined by mass-spectrometry and polyacrylamide gel electrophoresis (Laemmli method). The purity and homogeneity of products as well as the content of related impurities (oligomers and fragments) were determined using gel filtration; N-glycosylation profile was analysed by hydrophilic HPLC, total sialic acid was quantified by the Svennerholm resorcinol method. Protein binding to fibrin and human fibrinogen was assessed by surface plasmon resonance, and the specific activity was compared by fibrin clot lysis. Results: the research demonstrated a complete overlap of the products’ peptide maps, which indicates the identity of аlteplase amino acid sequences in the two medicines being compared. The authors of the study also determined the molecular weight and the content of the intact single-stranded form of the protein, and quantified post-translational modifications, the content of sialic acids and neutral sugars. The analysis of the N-glycosylation profile revealed insignificant differences in the percentage of multiantenna complex glycans. The specificity of alteplase was evaluated by analysing the formation of protein complexes with natural alteplase ligands – fibrin and plasminogen activator inhibitor-1, but no significant differences were found. The comparison of specific activation of plasminogen fibrinolytic activity was performed based on the results of the assay analysing the fibrin clot lysis rate, and it demonstrated comparability of Revelyse® and Actilyse®. Conclusions: comparative experimental studies have shown no differences in the structure, charge distribution heterogeneity, impurities content, and specific activity of alteplase as a component of Revelyse® and the reference product Actilyse®, which leads to the conclusion that they are similar in terms of physicochemical and biological properties. |
| first_indexed | 2024-03-08T21:44:31Z |
| format | Article |
| id | doaj.art-de43b67d77524d59972f919586d09234 |
| institution | Directory Open Access Journal |
| issn | 2221-996X 2619-1156 |
| language | Russian |
| last_indexed | 2025-03-14T10:52:28Z |
| publishDate | 2019-03-01 |
| publisher | Ministry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» |
| record_format | Article |
| series | Биопрепараты: Профилактика, диагностика, лечение |
| spelling | doaj.art-de43b67d77524d59972f919586d092342025-03-02T10:49:20ZrusMinistry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»Биопрепараты: Профилактика, диагностика, лечение2221-996X2619-11562019-03-01191394910.30895/2221-996X-2019-19-1-39-49160Physico-Chemical and Biological Properties of Biosimilar and Reference Tissue Plasminogen Activator ProductsV. D. Gusarova0M. S. Pantyushenko1V. M. Simonov2R. R. Shukurov3R. A. Khamitov4A. Yu. Vishnevskiy5International Biotechnology Center «GENERIUM»International Biotechnology Center «GENERIUM»International Biotechnology Center «GENERIUM»International Biotechnology Center «GENERIUM»International Biotechnology Center «GENERIUM»International Biotechnology Center «GENERIUM»Recombinant tissue plasminogen activator (international nonproprietary name — alteplase) which was developed by «GENERIUM» (Russia) and received a marketing authorisation in Russia is completely analogous to Actilyse® which is used to treat medical conditions accompanied by thrombosis, such as acute myocardial infarction, pulmonary embolism, and ischemic stroke. The aim of the study was to carry out a comprehensive comparison of physico-chemical and biological properties of Revelyse® and the reference product Actilyse® in order to assess their biosimilarity. Materials and Methods: comparative peptide mapping and determination of comparability of chromatographic profiles of tryptic hydrolysates was performed using RP-HPLC and massspectrometry; the molecular weight distribution was determined by mass-spectrometry and polyacrylamide gel electrophoresis (Laemmli method). The purity and homogeneity of products as well as the content of related impurities (oligomers and fragments) were determined using gel filtration; N-glycosylation profile was analysed by hydrophilic HPLC, total sialic acid was quantified by the Svennerholm resorcinol method. Protein binding to fibrin and human fibrinogen was assessed by surface plasmon resonance, and the specific activity was compared by fibrin clot lysis. Results: the research demonstrated a complete overlap of the products’ peptide maps, which indicates the identity of аlteplase amino acid sequences in the two medicines being compared. The authors of the study also determined the molecular weight and the content of the intact single-stranded form of the protein, and quantified post-translational modifications, the content of sialic acids and neutral sugars. The analysis of the N-glycosylation profile revealed insignificant differences in the percentage of multiantenna complex glycans. The specificity of alteplase was evaluated by analysing the formation of protein complexes with natural alteplase ligands – fibrin and plasminogen activator inhibitor-1, but no significant differences were found. The comparison of specific activation of plasminogen fibrinolytic activity was performed based on the results of the assay analysing the fibrin clot lysis rate, and it demonstrated comparability of Revelyse® and Actilyse®. Conclusions: comparative experimental studies have shown no differences in the structure, charge distribution heterogeneity, impurities content, and specific activity of alteplase as a component of Revelyse® and the reference product Actilyse®, which leads to the conclusion that they are similar in terms of physicochemical and biological properties.https://www.biopreparations.ru/jour/article/view/207tissue plasminogen activatorbiosimilaractilyse®revelyse®glycosylation profilepost-translational modificationsfibrin clot lysis |
| spellingShingle | V. D. Gusarova M. S. Pantyushenko V. M. Simonov R. R. Shukurov R. A. Khamitov A. Yu. Vishnevskiy Physico-Chemical and Biological Properties of Biosimilar and Reference Tissue Plasminogen Activator Products Биопрепараты: Профилактика, диагностика, лечение tissue plasminogen activator biosimilar actilyse® revelyse® glycosylation profile post-translational modifications fibrin clot lysis |
| title | Physico-Chemical and Biological Properties of Biosimilar and Reference Tissue Plasminogen Activator Products |
| title_full | Physico-Chemical and Biological Properties of Biosimilar and Reference Tissue Plasminogen Activator Products |
| title_fullStr | Physico-Chemical and Biological Properties of Biosimilar and Reference Tissue Plasminogen Activator Products |
| title_full_unstemmed | Physico-Chemical and Biological Properties of Biosimilar and Reference Tissue Plasminogen Activator Products |
| title_short | Physico-Chemical and Biological Properties of Biosimilar and Reference Tissue Plasminogen Activator Products |
| title_sort | physico chemical and biological properties of biosimilar and reference tissue plasminogen activator products |
| topic | tissue plasminogen activator biosimilar actilyse® revelyse® glycosylation profile post-translational modifications fibrin clot lysis |
| url | https://www.biopreparations.ru/jour/article/view/207 |
| work_keys_str_mv | AT vdgusarova physicochemicalandbiologicalpropertiesofbiosimilarandreferencetissueplasminogenactivatorproducts AT mspantyushenko physicochemicalandbiologicalpropertiesofbiosimilarandreferencetissueplasminogenactivatorproducts AT vmsimonov physicochemicalandbiologicalpropertiesofbiosimilarandreferencetissueplasminogenactivatorproducts AT rrshukurov physicochemicalandbiologicalpropertiesofbiosimilarandreferencetissueplasminogenactivatorproducts AT rakhamitov physicochemicalandbiologicalpropertiesofbiosimilarandreferencetissueplasminogenactivatorproducts AT ayuvishnevskiy physicochemicalandbiologicalpropertiesofbiosimilarandreferencetissueplasminogenactivatorproducts |